Cogent Biosciences Inc
$ 34.00
-3.76%
13 Mar - close price
- Market Cap 5,518,500,000 USD
- Current Price $ 34.00
- High / Low $ 37.10 / 33.91
- Stock P/E N/A
- Book Value 3.40
- EPS -2.16
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.74 %
- 52 Week High 43.73
- 52 Week Low 3.72
About
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$53.58
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-03 | 2025-08-05 | 2025-05-05 | 2025-02-24 | 2024-10-31 | 2024-08-06 | 2024-05-07 | 2024-02-26 | 2023-11-02 | 2023-08-08 | 2023-05-09 | 2023-03-14 |
| Reported EPS | -0.5 | -1.27 | -0.5249 | -0.09 | -0.6412 | -0.59 | -0.62 | -0.63 | -0.64 | -0.59 | -0.54 | -0.56 |
| Estimated EPS | -0.5217 | -0.5867 | -0.5771 | -0.5837 | -0.5664 | -0.56 | -0.52 | -0.56 | -0.5 | -0.54 | -0.57 | -0.52 |
| Surprise | 0.0217 | -0.6833 | 0.0522 | 0.4937 | -0.0748 | -0.03 | -0.1 | -0.07 | -0.14 | -0.05 | 0.03 | -0.04 |
| Surprise Percentage | 4.1595% | -116.465% | 9.0452% | 84.5811% | -13.2062% | -5.3571% | -19.2308% | -12.5% | -28% | -9.2593% | 5.2632% | -7.6923% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.52 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: COGT
2026-03-14 14:29:00
Cogent Biosciences (NASDAQ: COGT) is highlighted as a top multibagger stock favored by billionaires, driven by strong regulatory momentum for its lead candidate, bezuclastinib. The company has submitted multiple New Drug Applications (NDAs) for severe mastocytosis and gastrointestinal stromal tumors, supported by robust clinical trial data. With substantial cash reserves from a recent offering, Cogent is well-funded to advance its diverse pipeline of precision therapies into 2028.
2026-03-12 03:52:30
The article provides a detailed analysis of Cogent Biosciences Inc. (NASDAQ: COGT), highlighting weak near and mid-term sentiment but a strong long-term positive outlook. It presents various AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis with specific support and resistance levels. The report emphasizes an exceptional risk-reward setup targeting a 22.1% gain versus 0.3% risk.
2026-03-10 20:51:51
Cogent Biosciences (COGT) is under investor scrutiny after releasing new SUMMIT trial data for bezuclastinib, impacting its prior share price momentum. Despite significant past gains, the market is assessing whether the 10.9x Price-to-Book ratio is justified, given the company's unprofitability and reliance on future pipeline success, particularly compared to industry averages and peer valuations. The article suggests investors monitor potential clinical setbacks and further shareholder dilution but notes the P/B is considered "ABOUT RIGHT" when compared to a specific peer group.
2026-03-09 18:39:00
Cogent Biosciences' (COGT) shares are under scrutiny after new SUMMIT trial data for bezuclastinib in NonAdvanced Systemic Mastocytosis. Despite significant past returns, current trading at a 10.9x Price-to-Book ratio, much higher than the biotech industry average of 2.7x, suggests investors are placing high value on its pipeline. The company is unprofitable with growing losses, indicating that the market anticipates future success from its drug programs like bezuclastinib, but also highlighting risks of clinical setbacks and shareholder dilution.
2026-03-07 17:53:01
This article reports that Cogent Biosciences (COGT) has received Breakthrough Therapy Designation (BTD) from the FDA for its bezuclastinib-sunitinib combination therapy. This designation aims to accelerate the development and review of the treatment, which is designed for a serious condition.
2026-03-07 15:52:26
Cogent Biosciences reported positive 48-week clinical results for bezuclastinib in NonAdvanced Systemic Mastocytosis, showing significant improvements in symptoms, biomarkers, and bone mineral density. This data strengthens the investment case by reinforcing the therapy's clinical relevance and potential for disease modification. However, the company faces challenges including rising losses, dilution pressures, and potential overvaluation of its shares, despite the promising clinical advancements.
